<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180813</url>
  </required_header>
  <id_info>
    <org_study_id>1218-0184</org_study_id>
    <nct_id>NCT04180813</nct_id>
  </id_info>
  <brief_title>Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose</brief_title>
  <official_title>A Non-interventional Study of Patient Medication Adherence and Treatment Effectiveness Among New Users of Linagliptin and Acarbose in the Real-world Clinical Setting in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional cohort study based on newly collected data under routine medical practice&#xD;
      of a total of 500 Diabetes Mellitus, Type 2 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of T2DM patients with high medication adherence with MMAS-8 questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Highly adherent patients were identified with the score of 8 on the scale, medium adherers with a score of &gt;=6 and &lt;8, and low adherers with a score of &lt; 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effectiveness of linagliptin and acarbose on glycemic control evaluated by reducing HbA1c during a 24 week follow-up in two groups</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of T2DM patients achieving a therapeutic glycemic response defined as HbA1c &lt; 7.0% or a lowering of HbA1c ≥ 0.5%</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the composite endpoint (proportion of achieving HbA1c &lt; 7.0% without gastrointestinal adverse events (GI AEs) and without an investigator defined hypoglycaemic event)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 500 outpatients with T2DM from 16 sites distributed in different regions in&#xD;
        mainland China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient should fully know and understand the content of consent form, and the patient&#xD;
             is willing and able to sign an informed consent form&#xD;
&#xD;
          -  Chinese outpatients with confirmed T2DM&#xD;
&#xD;
          -  Patients of ≥ 18, &lt; 80 years old&#xD;
&#xD;
          -  Patients currently use metformin monotherapy ≥ 1500 mg/day or maximum tolerable dose&#xD;
             and whose glucose levels are not adequately controlled&#xD;
&#xD;
          -  HbA1c ≥ 7% and &lt; 12%&#xD;
&#xD;
          -  New user* linagliptin or acarbose as combination therapy with metformin ≥ 1500 mg/day&#xD;
             or maximum tolerable dose *New user defined as a T2DM patient initiating linagliptin&#xD;
             or acarbose as an add-on therapy.&#xD;
&#xD;
        These are patients who are on metformin and whose glucose levels are not adequately&#xD;
        controlled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus patients who previously used any DPP-4 inhibitor/ GLP-1&#xD;
             receptor agonist at index date or any AGI at index date, are not eligible to&#xD;
             participate. Also excluded are patients who currently using any glucose-lowering agent&#xD;
             as monotherapy other than metformin.&#xD;
&#xD;
          -  Patients with clinically significant acute major organ or systemic disease or other&#xD;
             condition judged by the investigator that would create difficulty for the 24-week&#xD;
             follow-up.&#xD;
&#xD;
          -  Patients who participated in a clinical trial within 2 months prior to study enrolment&#xD;
             date.&#xD;
&#xD;
          -  Patients diagnosed with Type 1 diabetes mellitus, secondary diabetes or gestational&#xD;
             diabetes.&#xD;
&#xD;
          -  Current treatment with systemic steroids at time of informed consent or within 6 weeks&#xD;
             prior to informed consent.&#xD;
&#xD;
          -  Patients with known significant GI disease as judged by the study physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Civil Aviation General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No.731 Hospital of China Aerospace Science &amp; Industry Corp.</name>
      <address>
        <city>Beijing</city>
        <zip>100074</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongying People's Hospital</name>
      <address>
        <city>Dongying</city>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhangjiagang First People Hospital</name>
      <address>
        <city>Suzhou</city>
        <zip>215699</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

